Grandfield & Dodd’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $2.33M | Buy |
|
|||||
|
2025
Q2 | $2.07M | Sell |
|
|||||
|
2025
Q1 | $1.83M | Buy |
|
|||||
|
2024
Q4 | $2.2M | Buy |
|
|||||
|
2024
Q3 | $1.82M | Buy |
|
|||||
|
2024
Q2 | $2.14M | Sell |
|
|||||
|
2024
Q1 | $2.15M | Buy |
|
|||||
|
2023
Q4 | $2.03M | Buy |
|
|||||
|
2023
Q3 | $1.71M | Sell |
|
|||||
|
2023
Q2 | $1.44M | Buy |
|
|||||
|
2023
Q1 | $1.54M | Buy |
|
|||||
|
2022
Q4 | $1.78M | Buy |
|
|||||
|
2022
Q3 | $1.52M | Buy |
|
|||||
|
2022
Q2 | $1.36M | Buy |
|
|||||
|
2022
Q1 | $1.29M | Buy |
|
|||||
|
2021
Q4 | $1.13M | Buy |
|
|||||
|
2021
Q3 | $1.14M | Buy |
|
|||||
|
2021
Q2 | $1.14M | Buy |
|
|||||
|
2021
Q1 | $1.12M | Buy |
|
|||||
|
2020
Q4 | $1.09M | Buy |
|
|||||
|
2020
Q3 | $1.07M | Buy |
|
|||||
|
2020
Q2 | $1.35M | Buy |
|
|||||
|
2020
Q1 | $903K | Buy |
|
|||||
|
2019
Q4 | $1.08M | Buy |
|
|||||
|
2019
Q3 | $853K | Buy |
|
|||||
|
2019
Q2 | $727K | Buy |
|
|||||
|
2019
Q1 | $694K | Buy |
|
|||||
|
2018
Q4 | $558K | Buy |
|
|||||
|
2018
Q3 | $953K | Buy |
|
|||||
|
2018
Q2 | $755K | Buy |
|
|||||
|
2018
Q1 | $634K | Sell |
|
|||||
|
2017
Q4 | $614K | Buy |
|
|||||
|
2017
Q3 | $466K | Buy |
|
|||||
|
2017
Q2 | $282K | Buy |
|
|||||
|
2017
Q1 | $230K | Buy |
|